Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0017 in Active Ankylosing Spondylitis (Phase II)
CTR20230990Phase 2Completed
- Sponsor
- Huabo Biopharm
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of HB0017 in ankylosing spondylitis (AS), sponsored by Huabo Biopharm. Started Apr 2023; status: completed.
02
Drugs
HB0017
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20230990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230990.